Contact
Please use this form to send email to PR contact of this press release:
OSE Immunotherapeutics Signs a License Option Agreement with Inserm to Develop a New Cancer Immunotherapy Targeting Myeloid Cells
TO:
Please use this form to send email to PR contact of this press release:
OSE Immunotherapeutics Signs a License Option Agreement with Inserm to Develop a New Cancer Immunotherapy Targeting Myeloid Cells
TO: